Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Vineet Laboratories's Enterprise Value for the quarter that ended in Dec. 2025 was ₹403.5 Mil.
Vineet Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-62.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vineet Laboratories EV-to-EBIT Related Terms
Vineet Laboratories EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Vineet Laboratories's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, Vineet Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vineet Laboratories EV-to-EBIT vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Vineet Laboratories's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Vineet Laboratories's EV-to-EBIT falls into.
Vineet Laboratories's current Enterprise Value is ₹1,172.2 Mil.
Vineet Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-62.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vineet Laboratories (NSE:VINEETLAB) has a EV-to-EBIT of -18.65 as of Aug. 02, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vineet Laboratories and its competitors. According to the industry distribution chart, Vineet Laboratories ranks #999999 out of 1241 companies in the Chemicals industry.
Is Vineet Laboratories' EV-to-EBIT too high?
Vineet Laboratories' current EV-to-EBIT is -18.65. Based on the distribution chart, Vineet Laboratories ranks #999999 out of 1241 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, Vineet Laboratories has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vineet Laboratories' EV-to-EBIT compare to DOW?
According to the Chemicals industry distribution chart, Vineet Laboratories ranks #999999 out of 1241 companies for EV-to-EBIT. This places Vineet Laboratories in the lower half of its industry. The industry median EV-to-EBIT is 16.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Chemicals company?
The median EV-to-EBIT among Chemicals companies is 16.86, based on 1,241 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vineet Laboratories and its competitors. For the Chemicals industry, the median EV-to-EBIT is 16.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vineet Laboratories's current EV-to-EBIT is -18.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vineet Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Vineet Laboratories (NSE:VINEETLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹15.11, compared to a current price of ₹39.63 — trading 162.3% above its estimated fair value. The current EV-to-EBIT is -18.65. Vineet Laboratories' overall GF Score™ is 38/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Vineet Laboratories (NSE:VINEETLAB), the current EV-to-EBIT is -18.65 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vineet Laboratories (NSE:VINEETLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Vineet Laboratories stock appears to be overvalued.
The current stock price of ₹39.63 is trading 162.3% above its estimated GF Value™ of ₹15.11.
GuruFocus considers Vineet Laboratories to be Significantly Overvalued.
Key valuation signals for NSE:VINEETLAB:
EV-to-EBIT: -18.65
GF Value™: ₹15.11 vs. price of ₹39.63 (162.3% above fair value)
No single metric tells the full story. See the NSE:VINEETLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vineet Laboratories Ltd is engaged in the business of Pharmaceutical intermediates and Fine chemicals. The products of the companies include Dimethyl phenoxy acetyl chloride, Dimethyl Phenoxy Acetic Acid, Nitrophenyl phosphate disodium salt, and others. Geographically, the company operates within India and outside India, with a majority of revenue coming from India. The company has one business segment, the manufacture of Drug Intermediates & Bulk Dugs.
38GF Score
Get the complete analysis for NSE:VINEETLAB
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VINEETLAB has been successfully added to your 
